Recent investigations have focused on the overlap of GLP-1|GIP|glucagon receptor agonist therapies and DA signaling. While GIP agonists are widely employed for treating type 2 diabetes, their unexpected consequences on https://victorrtyb801039.thechapblog.com/39972308/emerging-gcgr-stimulators-and-dopaminergic-modulation-a-comparative-overview